This announcement is a separate document:
6-K: Gsk Presents Positive Data for Arexvy, Its Respiratory Syncytial Virus (Rsv) Vaccine, Indicating Protection over Three Rsv Seasons
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.